周五盘中，宜明昂科-B（01541.HK）股价出现大幅上涨，涨幅高达9.73%，引起市场广泛关注。这一显著涨幅与公司最新发布的临床试验进展密切相关。
根据公司公告，宜明昂科-B与Instil Bio, Inc.（TIL）联合宣布了IMM2510/AXN-2510的临床最新情况及未来计划。IMM2510/AXN-2510是一种PD-L1和VEGF的双特异性抗体，目前正在开发用于治疗多种实体肿瘤癌症。公司预计将于今年第三季度在中国内地完成IMM2510/AXN-2510联合化疗治疗一线NSCLC（非小细胞肺癌）患者的2期试验，约60名患者入组。更值得关注的是，该2期试验的初步安全性及有效性结果预计将于今年下半年公布。
此外，公司还透露，3期试验预计将于明年年中在中国内地启动，目前正在与监管部门进行商讨。这一系列积极的临床试验进展无疑增强了投资者对宜明昂科-B未来发展前景的信心，从而推动了股价的大幅上涨。随着更多临床数据的公布和后续试验的推进，市场将继续密切关注宜明昂科-B的研发进展及其在肿瘤治疗领域的潜在突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.